Chardan lowered the firm’s price target on Forte Biosciences (FBRX) to $61 from $64 and keeps a Buy rating on the shares. The firm updates its model after the company’s FY24 update and expectations of Celiac Disease data expected in Q2.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBRX: